Jacobs Levy Equity Management, Inc Crinetics Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $469,922 - $702,377	-27,839 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$15.9 - $21.15 $720,540 - $958,454	-45,317 Reduced 61.95%	27,839 $525,000
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $205,990 - $271,814	-15,488 Reduced 17.47%	73,156 $1.12 Million
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $1.07 Million - $1.55 Million	88,644 New	88,644 $1.25 Million

241

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.